There is evidence that combination therapies targeting tumors harboring BRCA mutations—such as PARP inhibitors—with PI3K pathway inhibition therapies may exhibit synergy in vivo for the treatment of endogenous BRCA1-related breast cancer mouse model (17). Here, BRCA1 is linked to breast cancer.